EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.
S. Verma
Honoraria - GlaxoSmithKline; Roche
Research Funding - Roche; Sanofi
V. Dieras
Consultant or Advisory Role - Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche (U); Sanofi
Honoraria - Eisai; Genentech; GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
L. Gianni
Consultant or Advisory Role - Boehringer Ingelheim; Eisai; Genentech; GlaxoSmithKline; Merrimack; Pfizer; Roche; Wyeth
D. Miles
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche
M. Welslau
No relevant relationships to disclose
M. D. Pegram
Consultant or Advisory Role - Takeda (U)
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - Sanofi
Expert Testimony - Novartis (U)
Other Remuneration - Bristol-Myers Squibb; Pfizer; Roche/Genentech
J. Baselga
No relevant relationships to disclose
E. Guardino
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
L. Fang
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
C. M. Linehan
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
K. L. Blackwell
Consultant or Advisory Role - Genentech